Dash Bio is a preclinical and clinical bioanalysis company that leverages a fully automated bioanalysis platform to enhance the speed, precision, and scalability of drug development. The company focuses on transforming the drug development process through innovative tech-enabled services, aiming to streamline and accelerate bioanalytical workflows.
Key Executives
Dash Bio had 49 employees as of October 12, 2026. The number of employees increased by 3 (6.52%) week-over-week.
Dash Bio had 8,350 followers as of October 12, 2026. The number of followers increased by 36 (0.43%) week-over-week.
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 12, 2026 | Series A | $30.00M | ― |
| Aug 14, 2025 | Seed Round | $6.50M | ― |
| Jul 23, 2025 | Investment | $11.00M | ― |
| Investor Name | Funding Round |
|---|---|
| Freestyle Capital | Seed Round |
| Swift Ventures | Seed Round |
| LifeX Ventures | Seed Round |
| Freestyle Capital | Investment |
| Swift Ventures | Investment |
| LifeX Ventures | Investment |
| The Aligned Fund | Investment |
| Cybernetix Ventures | Investment |
A snapshot of private companies similar to Dash Bio, helping you discover and navigate related company profiles.